ArticleJournal of cancer research and clinical oncology2025
Targeted therapies in primary vaginal cancer.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePrimary vaginal cancer (PVC) accounts for 1–2% of all gynecological malignancies. Therefore, clinical trials lack and there is a paucity of approved medications beyond radiation or chemoradiation as main first line therapy. The GOG 240 and the Keynote 826 have shown significant improvements in survival in cervical cancer patients. Both concepts are approved medications for the treatment of advanced, recurrent or metastastic cervical cancer. However, the efficacy of Bevacizumab and Pembrolizumab and other Immunotherapies in PVC is mainly unknown. This study evaluates the efficacy and potential of targeted therapies and immunotherapies in patients with metastatic primary vaginal cancer, based on therapeutic strategies established for cervical cancer.
methodsIn this retrospective study, 6 patients with metastatic PVC were treated with Carboplatin/Paclitaxel/Bevacizumab with or without Pembrolizumab. Due to Her2neu expression one patient was treated with Her2neu targeted therapy and one patient is on Nivolumab at present.
results4 patients received Bevacizumab (Bev) in addition to Carboplatin (C) and Paclitaxel (Pac). Duration of response was 6 and 13 month and one patient is still on Bev. One patient progressed after 5 cycles of C/P/Bev. 2 Patients were treated with Pembrolizumab (P) mono after C/Pac/Bev. One out of 2 patients showed a duration of response of 36 month despite late stage metastatic disease. Local progress was controlled by adjunct local radiation therapy. The other patient progressed and died. Two patients were treated with C/Pac/Bev/P. One patient is still on therapy and one patient has died due to progressive disease. One patient is on Nivolumab with good response.
conclusionThese data provide a proof of concept to adopt therapeutic modalities from cervical cancer patients in PVC patients. In addition, our findings underscore the importance of collecting real-world data to guide clinical decision-making in metastatic primary vaginal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.